Ipilimumab for the treatment of metastatic prostate cancer
Ipilimumab for the treatment of metastatic prostate cancer
复制标题
DOI：
10.1080/14712598.2018.1420777
复制
发表时间：
2018-01-01
影响因子：
4.6
通讯作者：
Caraglia, Michele
中科院分区：
文献类型：
--
作者：
Alaia, Concetta;Boccellino, Mariarosaria;Caraglia, Michele
简介：检查点抑制剂免疫疗法开始被认为是化疗失败时治疗转移性前列腺癌 (PCa) 的有效武器。 Ipilimumab (ipi) 是一种完全人源化的单克隆抗体，可阻断 CTLA4 的活性。它的分子量为 148 kDa，在生理 pH 值下呈水溶性。 IPI 最初被 FDA 批准用于治疗恶性黑色素瘤，目前正在转移性去势抵抗性前列腺癌中进行研究，并取得了有希望的早期结果。涵盖领域：本次综述的目的是整理现有最重要的 IPI 临床前和临床研究，以提出未来的新策略。专家意见：需要进行更多研究来降低 PCa 中 IPI 的毒性并增加其活性。一种可能的策略是将 iPI 与标准抗癌疗法（例如疫苗、PDL1 抑制剂、抗雄激素药物和化疗药物）相结合。一些初步结果表明，联合策略有助于提高 mCRPC 的活性，即使治疗的毒性可能会增加。联合治疗的活性仍然无法预测，但考虑到正在进行的研究，我们相信它们具有良好的潜力，将导致最佳治疗策略的发现。
Introduction: Immunotherapy with checkpoint inhibitors is beginning to be recognized as a valid weapon for the treatment of metastatic prostate cancer (PCa) when chemotherapy fails. Ipilimumab (ipi) is a fully humanized monoclonal antibody that blocks the activity of CTLA4. It also has a molecular weight of 148 kDa and is water-soluble at physiological pH. Ipi was first approved by the FDA for the treatment of malignant melanoma and is currently being studied in metastatic castration-resistant prostate cancer, with promising early results.Areas covered: The aim of this review is to collate the most significant preclinical and clinical studies available that look at ipi to propose new strategies for the future.Expert opinion: Additional studies are required to reduce toxicity and increase the activity of ipi in PCa. A possible strategy is to combine ipi with standard anti-cancer therapeutics such as vaccines, PDL1 inhibitors, antiandrogen drugs, and chemotherapy agents. Several initial results have suggested that combination strategies are useful to increase the activity in mCRPC, even if the toxicity of the treatment can increase. The activity of combined treatments is still not predictable, but considering the ongoing studies, we believe that they have good potential that will lead to the discovery of an optimal therapeutic strategy.